Areas of Focus
- Immunopharmacology
- Clinical Chinese Medicine
Work Experience
- 2023-10~Present - Shanghai Institute of Materia Medica - Researcher
- 2008-10~2023-09 - Shanghai Institute of Materia Medica - Associate Researcher
- 2006-07~2008-09 - Shanghai Institute of Materia Medica - Assistant Researcher
- 2024-01-15~Present - Nanjing University of Chinese Medicine - Graduate Advisor
Academic Background & Achievements
- 2003-09--2006-07 Ph.D.: Shanghai Institute of Materia Medica
- 2000-09--2003-07 Master's Degree: Jilin University
- 1996-09--2000-07 Bachelor's Degree: Jilin University
Publications
- Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster, 3rd Author, 2023
- ACE2-Targeting Antibody Suppresses SARS-CoV-2 Omicron and Delta Variants, Not mentioned, 2022
- PD-L1/TIGIT bispecific antibody showed survival advantage in animal model, Not mentioned, 2022
- Tyrphostin A9 protects axons in experimental autoimmune encephalomyelitis through activation of ERKs, Not mentioned, 2022
- ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker, 4th Author, 2021
- Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion, 3rd Author, 2014
- Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus, 2nd Author, 2011
- Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro, 1st Author, 2009
- Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors, 3rd Author, 2008
- Anti-Hepatitis B Virus Drugs in Clinical and Preclinical Development, 1st Author, 2008
- Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus, 2nd Author, 2007
- Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives, 2nd Author, 2006
